383 related articles for article (PubMed ID: 23623482)
21. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
[TBL] [Abstract][Full Text] [Related]
24. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
[TBL] [Abstract][Full Text] [Related]
25. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
[TBL] [Abstract][Full Text] [Related]
26. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for type I glycogen storage diseases.
Chou JY; Mansfield BC
Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.
Lee YM; Conlon TJ; Specht A; Coleman KE; Brown LM; Estrella AM; Dambska M; Dahlberg KR; Weinstein DA
J Inherit Metab Dis; 2018 Nov; 41(6):977-984. PubMed ID: 29802554
[TBL] [Abstract][Full Text] [Related]
29. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.
Chou JY; Jun HS; Mansfield BC
Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743
[TBL] [Abstract][Full Text] [Related]
30. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
[TBL] [Abstract][Full Text] [Related]
31. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
32. In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.
Koeberl DD
J Inherit Metab Dis; 2012 Jul; 35(4):671-8. PubMed ID: 22310927
[TBL] [Abstract][Full Text] [Related]
33. [Heterogeneous phenotypes in Chinese glycogen storage disease type Ia patients with homozygous G727T mutation].
Qiu ZQ; Wei M; Liu G; Liu GY
Zhonghua Er Ke Za Zhi; 2003 Apr; 41(4):252-5. PubMed ID: 14754525
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
[TBL] [Abstract][Full Text] [Related]
35. Molecular biology and gene therapy for glycogen storage disease type Ib.
Chou JY; Cho JH; Kim GY; Mansfield BC
J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
[TBL] [Abstract][Full Text] [Related]
37. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
[TBL] [Abstract][Full Text] [Related]
38. The molecular basis of type 1 glycogen storage diseases.
Chou JY
Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241
[TBL] [Abstract][Full Text] [Related]
39. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
[TBL] [Abstract][Full Text] [Related]
40. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
Chou JY; Matern D; Mansfield BC; Chen YT
Curr Mol Med; 2002 Mar; 2(2):121-43. PubMed ID: 11949931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
